Current Molecular Medicine

Author(s): Afzal Ansari, Suman Kumar Ray, Mukul Sharma, Rakesh Rawal* and Pushpendra Singh*

DOI: 10.2174/0115665240266906231024111920

DownloadDownload PDF Flyer Cite As
Tumor Mutational Burden as a Biomarker of Immunotherapy Response: An Immunogram Approach in Onco-immunology

Page: [1461 - 1469] Pages: 9

  • * (Excluding Mailing and Handling)

Abstract

Immune checkpoint inhibitors have revolutionized cancer treatment by allowing T cells to reactivate. Tumor mutational burden (TMB) is a biomarker that has emerged as a viable diagnostic for locating patients who would benefit from immunotherapy in particular cancer types. Greater neo-antigens mean more opportunities for T cell identification, and TMB is clinically linked to better immune checkpoint inhibitors. Tumor foreignness is a cancer immunogram, and TMB can be used as a substitute for foreignness. The role of TMB analysis as an independent predictor of immunotherapy response in the context of immune checkpoint inhibitor medications is the subject of this mini-review.

Keywords: Tumor mutational burden, biomarkers, immune checkpoint inhibitor, neo-antigens, immunotherapies.